nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Ill-defined disorder—Dactinomycin—uterine cancer	0.00228	0.00228	CcSEcCtD
Degarelix—Nocturia—Doxorubicin—uterine cancer	0.00227	0.00227	CcSEcCtD
Degarelix—Anaemia—Dactinomycin—uterine cancer	0.00227	0.00227	CcSEcCtD
Degarelix—Injection site reaction—Epirubicin—uterine cancer	0.00226	0.00226	CcSEcCtD
Degarelix—Urticaria—Progesterone—uterine cancer	0.00225	0.00225	CcSEcCtD
Degarelix—Acute coronary syndrome—Etoposide—uterine cancer	0.00224	0.00224	CcSEcCtD
Degarelix—Abdominal pain—Progesterone—uterine cancer	0.00224	0.00224	CcSEcCtD
Degarelix—Body temperature increased—Progesterone—uterine cancer	0.00224	0.00224	CcSEcCtD
Degarelix—Renal failure—Etoposide—uterine cancer	0.00223	0.00223	CcSEcCtD
Degarelix—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.00223	CcSEcCtD
Degarelix—Blood bilirubin increased—Doxorubicin—uterine cancer	0.00223	0.00223	CcSEcCtD
Degarelix—Myocardial infarction—Etoposide—uterine cancer	0.00223	0.00223	CcSEcCtD
Degarelix—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00222	0.00222	CcSEcCtD
Degarelix—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.00221	0.00221	CcSEcCtD
Degarelix—Malaise—Dactinomycin—uterine cancer	0.00221	0.00221	CcSEcCtD
Degarelix—Influenza like illness—Epirubicin—uterine cancer	0.00221	0.00221	CcSEcCtD
Degarelix—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.0022	0.0022	CcSEcCtD
Degarelix—Inflammation—Doxorubicin—uterine cancer	0.00217	0.00217	CcSEcCtD
Degarelix—Hepatobiliary disease—Etoposide—uterine cancer	0.00215	0.00215	CcSEcCtD
Degarelix—Musculoskeletal pain—Doxorubicin—uterine cancer	0.00213	0.00213	CcSEcCtD
Degarelix—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00212	0.00212	CcSEcCtD
Degarelix—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.00211	0.00211	CcSEcCtD
Degarelix—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.0021	0.0021	CcSEcCtD
Degarelix—Injection site reaction—Doxorubicin—uterine cancer	0.00209	0.00209	CcSEcCtD
Degarelix—Hypersensitivity—Progesterone—uterine cancer	0.00209	0.00209	CcSEcCtD
Degarelix—Discomfort—Dactinomycin—uterine cancer	0.00206	0.00206	CcSEcCtD
Degarelix—Influenza like illness—Doxorubicin—uterine cancer	0.00205	0.00205	CcSEcCtD
Degarelix—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00204	0.00204	CcSEcCtD
Degarelix—Asthenia—Progesterone—uterine cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Hypoaesthesia—Etoposide—uterine cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Urinary tract disorder—Etoposide—uterine cancer	0.00201	0.00201	CcSEcCtD
Degarelix—Pruritus—Progesterone—uterine cancer	0.002	0.002	CcSEcCtD
Degarelix—Urethral disorder—Etoposide—uterine cancer	0.002	0.002	CcSEcCtD
Degarelix—Mental disability—Epirubicin—uterine cancer	0.00198	0.00198	CcSEcCtD
Degarelix—Diarrhoea—Progesterone—uterine cancer	0.00194	0.00194	CcSEcCtD
Degarelix—Eye disorder—Etoposide—uterine cancer	0.00191	0.00191	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.0019	0.0019	CcSEcCtD
Degarelix—Diabetes mellitus—Epirubicin—uterine cancer	0.0019	0.0019	CcSEcCtD
Degarelix—Cardiac disorder—Etoposide—uterine cancer	0.00189	0.00189	CcSEcCtD
Degarelix—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00189	0.00189	CcSEcCtD
Degarelix—Dizziness—Progesterone—uterine cancer	0.00187	0.00187	CcSEcCtD
Degarelix—Angiopathy—Etoposide—uterine cancer	0.00185	0.00185	CcSEcCtD
Degarelix—Immune system disorder—Etoposide—uterine cancer	0.00184	0.00184	CcSEcCtD
Degarelix—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00184	0.00184	CcSEcCtD
Degarelix—Mediastinal disorder—Etoposide—uterine cancer	0.00184	0.00184	CcSEcCtD
Degarelix—Chills—Etoposide—uterine cancer	0.00183	0.00183	CcSEcCtD
Degarelix—Mental disability—Doxorubicin—uterine cancer	0.00183	0.00183	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00182	0.00182	CcSEcCtD
Degarelix—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00182	0.00182	CcSEcCtD
Degarelix—Alopecia—Etoposide—uterine cancer	0.0018	0.0018	CcSEcCtD
Degarelix—Vomiting—Progesterone—uterine cancer	0.0018	0.0018	CcSEcCtD
Degarelix—Rash—Progesterone—uterine cancer	0.00179	0.00179	CcSEcCtD
Degarelix—Dermatitis—Progesterone—uterine cancer	0.00178	0.00178	CcSEcCtD
Degarelix—Headache—Progesterone—uterine cancer	0.00178	0.00178	CcSEcCtD
Degarelix—Hot flush—Epirubicin—uterine cancer	0.00177	0.00177	CcSEcCtD
Degarelix—Diabetes mellitus—Doxorubicin—uterine cancer	0.00176	0.00176	CcSEcCtD
Degarelix—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.00176	0.00176	CcSEcCtD
Degarelix—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00176	0.00176	CcSEcCtD
Degarelix—Menopausal symptoms—Epirubicin—uterine cancer	0.00175	0.00175	CcSEcCtD
Degarelix—Decreased appetite—Dactinomycin—uterine cancer	0.00174	0.00174	CcSEcCtD
Degarelix—Renal impairment—Epirubicin—uterine cancer	0.00174	0.00174	CcSEcCtD
Degarelix—Fatigue—Dactinomycin—uterine cancer	0.00173	0.00173	CcSEcCtD
Degarelix—Back pain—Etoposide—uterine cancer	0.00172	0.00172	CcSEcCtD
Degarelix—Pain—Dactinomycin—uterine cancer	0.00171	0.00171	CcSEcCtD
Degarelix—Muscle spasms—Etoposide—uterine cancer	0.00171	0.00171	CcSEcCtD
Degarelix—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.0017	0.0017	CcSEcCtD
Degarelix—Cardiac failure—Epirubicin—uterine cancer	0.00169	0.00169	CcSEcCtD
Degarelix—Nausea—Progesterone—uterine cancer	0.00168	0.00168	CcSEcCtD
Degarelix—Feeling abnormal—Dactinomycin—uterine cancer	0.00165	0.00165	CcSEcCtD
Degarelix—Ill-defined disorder—Etoposide—uterine cancer	0.00165	0.00165	CcSEcCtD
Degarelix—Anaemia—Etoposide—uterine cancer	0.00164	0.00164	CcSEcCtD
Degarelix—Gastrointestinal pain—Dactinomycin—uterine cancer	0.00164	0.00164	CcSEcCtD
Degarelix—Hot flush—Doxorubicin—uterine cancer	0.00164	0.00164	CcSEcCtD
Degarelix—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.00163	CcSEcCtD
Degarelix—Menopausal symptoms—Doxorubicin—uterine cancer	0.00162	0.00162	CcSEcCtD
Degarelix—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00162	CcSEcCtD
Degarelix—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00162	CcSEcCtD
Degarelix—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00161	CcSEcCtD
Degarelix—Renal impairment—Doxorubicin—uterine cancer	0.00161	0.00161	CcSEcCtD
Degarelix—Malaise—Etoposide—uterine cancer	0.0016	0.0016	CcSEcCtD
Degarelix—Abdominal pain—Dactinomycin—uterine cancer	0.00158	0.00158	CcSEcCtD
Degarelix—Body temperature increased—Dactinomycin—uterine cancer	0.00158	0.00158	CcSEcCtD
Degarelix—Cardiac failure—Doxorubicin—uterine cancer	0.00157	0.00157	CcSEcCtD
Degarelix—Hypertension—Etoposide—uterine cancer	0.00153	0.00153	CcSEcCtD
Degarelix—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00153	0.00153	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.0015	0.0015	CcSEcCtD
Degarelix—Discomfort—Etoposide—uterine cancer	0.00149	0.00149	CcSEcCtD
Degarelix—Breast disorder—Epirubicin—uterine cancer	0.00149	0.00149	CcSEcCtD
Degarelix—Hypersensitivity—Dactinomycin—uterine cancer	0.00148	0.00148	CcSEcCtD
Degarelix—Muscular weakness—Epirubicin—uterine cancer	0.00146	0.00146	CcSEcCtD
Degarelix—Anaphylactic shock—Etoposide—uterine cancer	0.00145	0.00145	CcSEcCtD
Degarelix—Asthenia—Dactinomycin—uterine cancer	0.00144	0.00144	CcSEcCtD
Degarelix—Skin disorder—Etoposide—uterine cancer	0.00141	0.00141	CcSEcCtD
Degarelix—Hyperhidrosis—Etoposide—uterine cancer	0.0014	0.0014	CcSEcCtD
Degarelix—Breast disorder—Doxorubicin—uterine cancer	0.00138	0.00138	CcSEcCtD
Degarelix—Diarrhoea—Dactinomycin—uterine cancer	0.00137	0.00137	CcSEcCtD
Degarelix—Hypotension—Etoposide—uterine cancer	0.00135	0.00135	CcSEcCtD
Degarelix—Muscular weakness—Doxorubicin—uterine cancer	0.00135	0.00135	CcSEcCtD
Degarelix—Dysuria—Epirubicin—uterine cancer	0.00134	0.00134	CcSEcCtD
Degarelix—Pollakiuria—Epirubicin—uterine cancer	0.00132	0.00132	CcSEcCtD
Degarelix—Weight increased—Epirubicin—uterine cancer	0.0013	0.0013	CcSEcCtD
Degarelix—Weight decreased—Epirubicin—uterine cancer	0.00129	0.00129	CcSEcCtD
Degarelix—Dyspnoea—Etoposide—uterine cancer	0.00129	0.00129	CcSEcCtD
Degarelix—Hyperglycaemia—Epirubicin—uterine cancer	0.00129	0.00129	CcSEcCtD
Degarelix—Vomiting—Dactinomycin—uterine cancer	0.00127	0.00127	CcSEcCtD
Degarelix—Rash—Dactinomycin—uterine cancer	0.00126	0.00126	CcSEcCtD
Degarelix—Decreased appetite—Etoposide—uterine cancer	0.00126	0.00126	CcSEcCtD
Degarelix—Renal failure—Epirubicin—uterine cancer	0.00125	0.00125	CcSEcCtD
Degarelix—Gastrointestinal disorder—Etoposide—uterine cancer	0.00125	0.00125	CcSEcCtD
Degarelix—Fatigue—Etoposide—uterine cancer	0.00125	0.00125	CcSEcCtD
Degarelix—Pain—Etoposide—uterine cancer	0.00124	0.00124	CcSEcCtD
Degarelix—Constipation—Etoposide—uterine cancer	0.00124	0.00124	CcSEcCtD
Degarelix—Urinary tract infection—Epirubicin—uterine cancer	0.00124	0.00124	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—uterine cancer	0.00124	0.00124	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—uterine cancer	0.00122	0.00122	CcSEcCtD
Degarelix—Hepatobiliary disease—Epirubicin—uterine cancer	0.0012	0.0012	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—uterine cancer	0.0012	0.0012	CcSEcCtD
Degarelix—Weight decreased—Doxorubicin—uterine cancer	0.0012	0.0012	CcSEcCtD
Degarelix—Feeling abnormal—Etoposide—uterine cancer	0.00119	0.00119	CcSEcCtD
Degarelix—Hyperglycaemia—Doxorubicin—uterine cancer	0.00119	0.00119	CcSEcCtD
Degarelix—Nausea—Dactinomycin—uterine cancer	0.00119	0.00119	CcSEcCtD
Degarelix—Gastrointestinal pain—Etoposide—uterine cancer	0.00119	0.00119	CcSEcCtD
Degarelix—Renal failure—Doxorubicin—uterine cancer	0.00116	0.00116	CcSEcCtD
Degarelix—Urticaria—Etoposide—uterine cancer	0.00115	0.00115	CcSEcCtD
Degarelix—Abdominal pain—Etoposide—uterine cancer	0.00115	0.00115	CcSEcCtD
Degarelix—Body temperature increased—Etoposide—uterine cancer	0.00115	0.00115	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—uterine cancer	0.00115	0.00115	CcSEcCtD
Degarelix—Hypoaesthesia—Epirubicin—uterine cancer	0.00114	0.00114	CcSEcCtD
Degarelix—Urinary tract disorder—Epirubicin—uterine cancer	0.00113	0.00113	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—uterine cancer	0.00113	0.00113	CcSEcCtD
Degarelix—Urethral disorder—Epirubicin—uterine cancer	0.00112	0.00112	CcSEcCtD
Degarelix—Hepatobiliary disease—Doxorubicin—uterine cancer	0.00111	0.00111	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—uterine cancer	0.00107	0.00107	CcSEcCtD
Degarelix—Hypersensitivity—Etoposide—uterine cancer	0.00107	0.00107	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—uterine cancer	0.00106	0.00106	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—uterine cancer	0.00105	0.00105	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—uterine cancer	0.00105	0.00105	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—uterine cancer	0.00104	0.00104	CcSEcCtD
Degarelix—Asthenia—Etoposide—uterine cancer	0.00104	0.00104	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—uterine cancer	0.00104	0.00104	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—uterine cancer	0.00104	0.00104	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—uterine cancer	0.00103	0.00103	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—uterine cancer	0.00103	0.00103	CcSEcCtD
Degarelix—Chills—Epirubicin—uterine cancer	0.00103	0.00103	CcSEcCtD
Degarelix—Pruritus—Etoposide—uterine cancer	0.00103	0.00103	CcSEcCtD
Degarelix—Arrhythmia—Epirubicin—uterine cancer	0.00102	0.00102	CcSEcCtD
Degarelix—Alopecia—Epirubicin—uterine cancer	0.00101	0.00101	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—uterine cancer	0.001	0.001	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—uterine cancer	0.000996	0.000996	CcSEcCtD
Degarelix—Erythema—Epirubicin—uterine cancer	0.000996	0.000996	CcSEcCtD
Degarelix—Diarrhoea—Etoposide—uterine cancer	0.000992	0.000992	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—uterine cancer	0.000989	0.000989	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—uterine cancer	0.000982	0.000982	CcSEcCtD
Degarelix—Back pain—Epirubicin—uterine cancer	0.000963	0.000963	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—uterine cancer	0.00096	0.00096	CcSEcCtD
Degarelix—Dizziness—Etoposide—uterine cancer	0.000959	0.000959	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—uterine cancer	0.000957	0.000957	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—uterine cancer	0.000956	0.000956	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—uterine cancer	0.000954	0.000954	CcSEcCtD
Degarelix—Chills—Doxorubicin—uterine cancer	0.00095	0.00095	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—uterine cancer	0.000945	0.000945	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—uterine cancer	0.000938	0.000938	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—uterine cancer	0.000935	0.000935	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—uterine cancer	0.000927	0.000927	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—uterine cancer	0.000924	0.000924	CcSEcCtD
Degarelix—Vomiting—Etoposide—uterine cancer	0.000922	0.000922	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—uterine cancer	0.000921	0.000921	CcSEcCtD
Degarelix—Erythema—Doxorubicin—uterine cancer	0.000921	0.000921	CcSEcCtD
Degarelix—Anaemia—Epirubicin—uterine cancer	0.00092	0.00092	CcSEcCtD
Degarelix—Rash—Etoposide—uterine cancer	0.000914	0.000914	CcSEcCtD
Degarelix—Dermatitis—Etoposide—uterine cancer	0.000913	0.000913	CcSEcCtD
Degarelix—Headache—Etoposide—uterine cancer	0.000908	0.000908	CcSEcCtD
Degarelix—Malaise—Epirubicin—uterine cancer	0.000898	0.000898	CcSEcCtD
Degarelix—Back pain—Doxorubicin—uterine cancer	0.000891	0.000891	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—uterine cancer	0.000886	0.000886	CcSEcCtD
Degarelix—Palpitations—Epirubicin—uterine cancer	0.00088	0.00088	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—uterine cancer	0.000868	0.000868	CcSEcCtD
Degarelix—Nausea—Etoposide—uterine cancer	0.000861	0.000861	CcSEcCtD
Degarelix—Hypertension—Epirubicin—uterine cancer	0.00086	0.00086	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—uterine cancer	0.000855	0.000855	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—uterine cancer	0.000851	0.000851	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—uterine cancer	0.000848	0.000848	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000842	0.000842	CcSEcCtD
Degarelix—Discomfort—Epirubicin—uterine cancer	0.000837	0.000837	CcSEcCtD
Degarelix—Malaise—Doxorubicin—uterine cancer	0.000831	0.000831	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—uterine cancer	0.000829	0.000829	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—uterine cancer	0.000814	0.000814	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—uterine cancer	0.000813	0.000813	CcSEcCtD
Degarelix—Nervous system disorder—Epirubicin—uterine cancer	0.000797	0.000797	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—uterine cancer	0.000795	0.000795	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—uterine cancer	0.000789	0.000789	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—uterine cancer	0.000786	0.000786	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—uterine cancer	0.000784	0.000784	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000779	0.000779	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—uterine cancer	0.000775	0.000775	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—uterine cancer	0.000767	0.000767	CcSEcCtD
Degarelix—Hypotension—Epirubicin—uterine cancer	0.000759	0.000759	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—uterine cancer	0.000752	0.000752	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00074	0.00074	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—uterine cancer	0.000737	0.000737	CcSEcCtD
Degarelix—Insomnia—Epirubicin—uterine cancer	0.000735	0.000735	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—uterine cancer	0.00073	0.00073	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—uterine cancer	0.000727	0.000727	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—uterine cancer	0.000724	0.000724	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—uterine cancer	0.000706	0.000706	CcSEcCtD
Degarelix—Hypotension—Doxorubicin—uterine cancer	0.000703	0.000703	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000701	0.000701	CcSEcCtD
Degarelix—Fatigue—Epirubicin—uterine cancer	0.000701	0.000701	CcSEcCtD
Degarelix—Pain—Epirubicin—uterine cancer	0.000695	0.000695	CcSEcCtD
Degarelix—Constipation—Epirubicin—uterine cancer	0.000695	0.000695	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000685	0.000685	CcSEcCtD
Degarelix—Insomnia—Doxorubicin—uterine cancer	0.00068	0.00068	CcSEcCtD
Degarelix—Dyspnoea—Doxorubicin—uterine cancer	0.00067	0.00067	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—uterine cancer	0.00067	0.00067	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—uterine cancer	0.000664	0.000664	CcSEcCtD
Degarelix—Decreased appetite—Doxorubicin—uterine cancer	0.000654	0.000654	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000649	0.000649	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—uterine cancer	0.000648	0.000648	CcSEcCtD
Degarelix—Urticaria—Epirubicin—uterine cancer	0.000645	0.000645	CcSEcCtD
Degarelix—Pain—Doxorubicin—uterine cancer	0.000643	0.000643	CcSEcCtD
Degarelix—Constipation—Doxorubicin—uterine cancer	0.000643	0.000643	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—uterine cancer	0.000642	0.000642	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—uterine cancer	0.000642	0.000642	CcSEcCtD
Degarelix—Feeling abnormal—Doxorubicin—uterine cancer	0.00062	0.00062	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000615	0.000615	CcSEcCtD
Degarelix—Hypersensitivity—Epirubicin—uterine cancer	0.000599	0.000599	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—uterine cancer	0.000597	0.000597	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—uterine cancer	0.000594	0.000594	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—uterine cancer	0.000594	0.000594	CcSEcCtD
Degarelix—Asthenia—Epirubicin—uterine cancer	0.000583	0.000583	CcSEcCtD
Degarelix—Pruritus—Epirubicin—uterine cancer	0.000575	0.000575	CcSEcCtD
Degarelix—Diarrhoea—Epirubicin—uterine cancer	0.000556	0.000556	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—uterine cancer	0.000554	0.000554	CcSEcCtD
Degarelix—Asthenia—Doxorubicin—uterine cancer	0.000539	0.000539	CcSEcCtD
Degarelix—Dizziness—Epirubicin—uterine cancer	0.000537	0.000537	CcSEcCtD
Degarelix—Pruritus—Doxorubicin—uterine cancer	0.000532	0.000532	CcSEcCtD
Degarelix—Vomiting—Epirubicin—uterine cancer	0.000517	0.000517	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—uterine cancer	0.000514	0.000514	CcSEcCtD
Degarelix—Rash—Epirubicin—uterine cancer	0.000512	0.000512	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—uterine cancer	0.000512	0.000512	CcSEcCtD
Degarelix—Headache—Epirubicin—uterine cancer	0.000509	0.000509	CcSEcCtD
Degarelix—Dizziness—Doxorubicin—uterine cancer	0.000497	0.000497	CcSEcCtD
Degarelix—Nausea—Epirubicin—uterine cancer	0.000483	0.000483	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—uterine cancer	0.000478	0.000478	CcSEcCtD
Degarelix—Rash—Doxorubicin—uterine cancer	0.000474	0.000474	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—uterine cancer	0.000474	0.000474	CcSEcCtD
Degarelix—Headache—Doxorubicin—uterine cancer	0.000471	0.000471	CcSEcCtD
Degarelix—Nausea—Doxorubicin—uterine cancer	0.000447	0.000447	CcSEcCtD
